A Safety, Tolerability, and Efficacy Study of E-islet 01 in Participants With Type 1 Diabetes

Prior treatment

• Participation in other clinical trials in the 3 months or islet cell transplant, organ transplant, or cell therapy in the 12 months prior to enrollment

Other illness

• Uncontrolled systemic infections, including but not limited to pulmonary tuberculosis, active hepatitis, a history of positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab), or Treponema pallidum antibody (TP-Ab).
• History of malignancy within the past 5 years or undergoing antitumor treatment

Other

• Other situations judged by the investigator as unsuitable for participation in the trial

• Clinical history of Type 1 Diabetes with \> 5 years of duration
• 2-hour C-peptide level \<0.3 ng/mL after a mixed meal stimulation test
• Under continuous insulin therapy, Participants have at least one of the following conditions:
  • At least one episode of documented severe hypoglycemia in the 12 months prior to enrollment;
  • Unaware hypoglycemia evaluated using the Clarke scoring system
• Willing and able to conduct self-blood glucose monitoring as required, with good compliance
• Voluntarily participate and sign the informed consent form